Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis

Sarcoidosis Clinical Trial

Official title:

Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03145922
• Other study ID #: 15-18171
• Status: Recruiting
• Start date: January 2016
• Est. completion date: January 2026

Study information

• Verified date: May 2020
• Source: National Jewish Health
• Contact: Victoria Wang, BS
• Phone: 4154769225
• Email: victoria.wang2[@]ucsf.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Sarcoidosis is a multi-system granulomatous disorder that is triggered and influenced by gene-environment interactions. Although sarcoidosis predominantly affects the lungs in most cases, the clinical disease course is highly variable and any organ can be affected leading to end organ damage despite currently available therapeutics that unfortunately also have numerous and potentially devastating side effects. The environmental triggers of sarcoidosis are unknown but several occupational, environmental and infectious agents have been associated with sarcoidosis in susceptible hosts. Exposure to these triggers result in inflammation, characterized by activation of CD4+ T-cells, cytokine production, subsequent recruitment of other immune cells, and granuloma formation. Although several genetic markers have been associated with sarcoidosis, none fully explain individual susceptibility or clinical course variability, strongly implicating the environment and epigenetics. We have the ability to generate a map of the epigenetic histone modifications in immune cells via Chromatin Immuno-Precipitation coupled with next generation sequencing (ChIP-seq) and a map of transcriptome profiles via RNA-seq. The availability of histone and transcriptional signatures defining T cell activity in sarcoidosis will help identify the specific molecular programs affected by disease processes and can become the basis for future discovery of novel biomarker diagnostics in a clinical setting.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 45
• Est. completion date: January 2026
• Est. primary completion date: January 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Between the ages of 18 and 85

• Diagnosis of sarcoidosis confirmed by either biopsy or by manifestations consistent with acute sarcoidosis in absence of other known diagnosis.

• Have a suspected diagnosis of sarcoidosis and is scheduled to undergo a biopsy procedure to confirm a diagnosis of sarcoidosis.

• Able to tolerate and willing to undergo study procedures

Exclusion Criteria:

• Current cigarette smoking or smoking within six months prior to the study

• Currently or recently (<6months) on immunosuppressive therapy

• Pregnancy

• Patient inability to participate in the study, such as undergo venipuncture and or BAL

Related Conditions & MeSH terms

• Sarcoidosis
• Sarcoidosis, Pulmonary

Intervention

Other:
• Observational Study
Observational study utilizing bronchoscopy, and imaging

Locations

Country	Name	City	State
United States	University of California, San Francisco (Parnassus)	San Francisco	California

Sponsors (3)

Lead Sponsor	Collaborator
National Jewish Health	University of California, San Francisco, University of Iowa

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Epigenomic Signature of Sarcoidosis	Determine the epigenomic signature of specific histone post-translational modifications associated with CD4+ T cell skewing and activity in sarcoidosis at the site of organ involvement via Chromatin Immuno-Precipitation coupled with next generation sequencing (ChIP-seq) and bronchoalveolar lavage (BAL).	5 years